New York, NY – According to filings with the U.S. Securities and Exchange Commission, Gilgamesh Pharmaceuticals is raising $2,434,845.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Jonathan Sporn played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Gilgamesh Pharmaceuticals

Gilgamesh is a serious mental health science focused, preclinical biotechnology company. We have a disciplined focus on developing innovative new chemical entities (NCE’s) leveraging a unique combination of medicinal chemistry, intellectual property strategy, neuroscience & neurobiology, and drug development expertise. We are an experienced team, with proven success in biotech exits and inventions.

To learn more about Gilgamesh Pharmaceuticals, visit http://www.gilgameshpharmaceutical.com/

Contact:
Jonathan Sporn, President and Chief Executive Officer
347-967-6831
https://www.linkedin.com/in/jonathan-sporn-4ba7802/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved